Study reveals many primary care physicians are unaware of new osteoporosis drug
A new medication, Prolia, was recently approved for the treatment of osteoporosis in postmenopausal women at increased risk of fractures or patients who have failed on or are intolerant to other osteoporosis treatment.
Recently, Decision Resources - a research and advisory firm for pharmaceutical and healthcare issues - conducted a study which found that three-quarters of surveyed endocrinologists and rheumatologists who are aware of Prolia anticipate prescribing the drug. However, while 94 percent of surveyed endocrinologists and 85 percent of surveyed rheumatologists are familiar with the drug, only 22 percent of primary care physicians say that they have heard of Prolia.
"Both surveyed endocrinologists and rheumatologists view Prolia as most likely to replace both oral and intravenously delivered bisphosphonates, such as Novartis's Reclast, in their treatment of osteoporosis," said Matthew Scutcher, a Decision Resources analyst. "Surveyed endocrinologists also believe Prolia will replace other osteoporosis drugs such as Eli Lilly's selective estrogen receptor modulator Evista."
Specialists largely anticipate prescribing it as a second- or third-line treatment for osteoporosis.